Viral Vector Production Market Size, Share, Trends, Growth Outlook

Viral Vector Production Market is estimated to increase at a growth rate of 17.5% CAGR over the forecast period from 2024 to 2030.

The global Viral Vector Production Marketstudy analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Indication (Cancer, Genetic Disorders, Infectious Diseases, Other Diseases), By Application (Gene Therapy, Vaccinology), By Viral Vector (Adenoviral Vectors, Lentiviral Vectors, Retroviral Vectors, Adeno-Associated Viral Vectors, Others).

An introduction to Viral Vector Production Market in 2024

The viral vector production market is experiencing significant growth in 2024, driven by advancements in gene therapy technologies, viral vector manufacturing processes, and the increasing demand for viral vectors as gene delivery vehicles for gene editing, gene transfer, and gene therapy applications in biopharmaceutical research, cell therapy development, and precision medicine initiatives. Viral vectors are genetically engineered viruses that are used to deliver therapeutic genes or genetic material into target cells, enabling the expression of desired proteins, correction of genetic defects, and modulation of cellular functions for therapeutic purposes. With the expansion of gene therapy pipelines, the development of novel viral vectors, and the scale-up of viral vector production platforms, the market is witnessing rapid expansion and adoption of viral vector production technologies, offering biopharmaceutical companies, research laboratories, and contract manufacturing organizations (CMOs) advanced and scalable solutions for viral vector manufacturing, purification, and characterization, driving advancements in gene therapy manufacturing and viral vector-based therapeutics.

Viral Vector Production Market Trend: Advancements in Viral Vector Manufacturing Technologies Reshape Viral Vector Production Market

A significant trend in the viral vector production market is the continuous advancements in manufacturing technologies. Viral vectors serve as crucial tools in gene therapy and vaccine development, driving the need for scalable and efficient production methods. Recent innovations in viral vector manufacturing, such as suspension cell culture systems, transient transfection techniques, and novel bioreactor designs, enable higher yields, enhanced purity, and streamlined downstream processing. Additionally, advancements in viral vector engineering, including capsid modifications and vector optimization strategies, further improve vector potency, transduction efficiency, and safety profiles. This trend reflects the industry's commitment to overcoming production challenges and optimizing viral vector manufacturing processes, driving market growth and innovation in gene therapy and vaccine production.

Viral Vector Production Market Driver: Rising Demand for Gene Therapy and Vaccine Development Propels Viral Vector Production Market Growth

The rising demand for gene therapy and vaccine development serves as a significant driver for the viral vector production market. Viral vectors, such as adeno-associated viruses (AAVs) and lentiviruses, play a crucial role in delivering therapeutic genes and antigens to target cells, enabling the treatment of genetic disorders, cancer, and infectious diseases. With the growing prevalence of genetic disorders, cancer incidence, and infectious disease outbreaks worldwide, there is an increasing need for effective gene therapies and vaccines. Additionally, advancements in gene editing technologies, such as CRISPR-Cas9, further expand the potential applications of viral vectors in precision medicine and personalized therapeutics. As biopharmaceutical companies and research institutions intensify efforts to develop novel gene therapies and vaccines, the demand for high-quality viral vectors continues to grow, supporting market expansion and technological advancements in viral vector production.

Viral Vector Production Market Opportunity: Expansion into Contract Development and Manufacturing Organization (CDMO) Services Presents Lucrative Opportunities in Viral Vector Production Market

The expansion into Contract Development and Manufacturing Organization (CDMO) services represents a promising opportunity for growth within the viral vector production market. As biopharmaceutical companies seek to accelerate their gene therapy and vaccine development programs, there is a growing demand for specialized expertise, infrastructure, and manufacturing capacity to support viral vector production. CDMOs offer a range of services, including process development, scale-up, cGMP manufacturing, and analytical testing, tailored to the specific needs of viral vector-based therapeutics. Moreover, CDMOs provide flexibility, speed-to-market, and cost-effectiveness, enabling biopharmaceutical companies to outsource viral vector production while focusing on core research and development activities. Capitalizing on this opportunity requires viral vector manufacturers to establish strategic partnerships, invest in manufacturing capabilities, and offer comprehensive CDMO services to meet the evolving needs of the gene therapy and vaccine development industry. Moreover, expanding geographical presence and diversifying service offerings can further enhance market competitiveness and revenue growth in the dynamic landscape of viral vector production.

Viral Vector Production Market Market Segmentation

By Indication
Cancer
Genetic Disorders
Infectious Diseases
Other Diseases
By Application
Gene Therapy
Vaccinology
By Viral Vector
Adenoviral Vectors
Lentiviral Vectors
Retroviral Vectors
Adeno-Associated Viral Vectors
Others

Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Viral Vector Production Market Companies

Addgene Inc
Advanced BioScience Laboratories Inc
Aldevron Llc
Audentes Therapeutics
Batavia Biosciences B.V.
BioMarin Pharmaceutical
BioNTech IMFS GmbH
Biovion oy
BlueBird Bio
Catalent Inc
Cell and Gene Therapy Catapult
CEVEC Pharmaceuticals GmbH
Cobra Biologics Ltd
Creative Biogene
FUJIFILM Diosynth Biotechnologies U.S.A. Inc
GE Healthcare
Genezen
Lonza
Merck KGaA
Miltenyi Biotec GmbH
Novasep Holding S.A.S
Orgenesis Biotech Israel Ltd
RegenxBio Inc
SIRION Biotech GmbH
Takara Bio.
Thermo Fisher Scientific
VGXI Inc
Vibalogics GmbH
Vigene Biosciences Inc
Virovek Incorporation
VIVEbiotech S.L.
Waisman Biomanufacturing
Wuxi AppTec Co. Ltd
YPOSKESI

Reasons to Buy the Viral Vector Production Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Viral Vector Production Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Viral Vector Production Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Viral Vector Production Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Viral Vector Production Market Size Outlook, $ Million, 2021 to 2030
3.2 Viral Vector Production Market Outlook by Type, $ Million, 2021 to 2030
3.3 Viral Vector Production Market Outlook by Product, $ Million, 2021 to 2030
3.4 Viral Vector Production Market Outlook by Application, $ Million, 2021 to 2030
3.5 Viral Vector Production Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Viral Vector Production Industry
4.2 Key Market Trends in Viral Vector Production Industry
4.3 Potential Opportunities in Viral Vector Production Industry
4.4 Key Challenges in Viral Vector Production Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Viral Vector Production Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Viral Vector Production Market Outlook by Segments
7.1 Viral Vector Production Market Outlook by Segments, $ Million, 2021- 2030
By Indication
Cancer
Genetic Disorders
Infectious Diseases
Other Diseases
By Application
Gene Therapy
Vaccinology
By Viral Vector
Adenoviral Vectors
Lentiviral Vectors
Retroviral Vectors
Adeno-Associated Viral Vectors
Others

8 North America Viral Vector Production Market Analysis and Outlook To 2030
8.1 Introduction to North America Viral Vector Production Markets in 2024
8.2 North America Viral Vector Production Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Viral Vector Production Market size Outlook by Segments, 2021-2030
By Indication
Cancer
Genetic Disorders
Infectious Diseases
Other Diseases
By Application
Gene Therapy
Vaccinology
By Viral Vector
Adenoviral Vectors
Lentiviral Vectors
Retroviral Vectors
Adeno-Associated Viral Vectors
Others

9 Europe Viral Vector Production Market Analysis and Outlook To 2030
9.1 Introduction to Europe Viral Vector Production Markets in 2024
9.2 Europe Viral Vector Production Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Viral Vector Production Market Size Outlook by Segments, 2021-2030
By Indication
Cancer
Genetic Disorders
Infectious Diseases
Other Diseases
By Application
Gene Therapy
Vaccinology
By Viral Vector
Adenoviral Vectors
Lentiviral Vectors
Retroviral Vectors
Adeno-Associated Viral Vectors
Others

10 Asia Pacific Viral Vector Production Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Viral Vector Production Markets in 2024
10.2 Asia Pacific Viral Vector Production Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Viral Vector Production Market size Outlook by Segments, 2021-2030
By Indication
Cancer
Genetic Disorders
Infectious Diseases
Other Diseases
By Application
Gene Therapy
Vaccinology
By Viral Vector
Adenoviral Vectors
Lentiviral Vectors
Retroviral Vectors
Adeno-Associated Viral Vectors
Others

11 South America Viral Vector Production Market Analysis and Outlook To 2030
11.1 Introduction to South America Viral Vector Production Markets in 2024
11.2 South America Viral Vector Production Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Viral Vector Production Market size Outlook by Segments, 2021-2030
By Indication
Cancer
Genetic Disorders
Infectious Diseases
Other Diseases
By Application
Gene Therapy
Vaccinology
By Viral Vector
Adenoviral Vectors
Lentiviral Vectors
Retroviral Vectors
Adeno-Associated Viral Vectors
Others

12 Middle East and Africa Viral Vector Production Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Viral Vector Production Markets in 2024
12.2 Middle East and Africa Viral Vector Production Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Viral Vector Production Market size Outlook by Segments, 2021-2030
By Indication
Cancer
Genetic Disorders
Infectious Diseases
Other Diseases
By Application
Gene Therapy
Vaccinology
By Viral Vector
Adenoviral Vectors
Lentiviral Vectors
Retroviral Vectors
Adeno-Associated Viral Vectors
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Addgene Inc
Advanced BioScience Laboratories Inc
Aldevron Llc
Audentes Therapeutics
Batavia Biosciences B.V.
BioMarin Pharmaceutical
BioNTech IMFS GmbH
Biovion oy
BlueBird Bio
Catalent Inc
Cell and Gene Therapy Catapult
CEVEC Pharmaceuticals GmbH
Cobra Biologics Ltd
Creative Biogene
FUJIFILM Diosynth Biotechnologies U.S.A. Inc
GE Healthcare
Genezen
Lonza
Merck KGaA
Miltenyi Biotec GmbH
Novasep Holding S.A.S
Orgenesis Biotech Israel Ltd
RegenxBio Inc
SIRION Biotech GmbH
Takara Bio.
Thermo Fisher Scientific
VGXI Inc
Vibalogics GmbH
Vigene Biosciences Inc
Virovek Incorporation
VIVEbiotech S.L.
Waisman Biomanufacturing
Wuxi AppTec Co. Ltd
YPOSKESI
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Indication
Cancer
Genetic Disorders
Infectious Diseases
Other Diseases
By Application
Gene Therapy
Vaccinology
By Viral Vector
Adenoviral Vectors
Lentiviral Vectors
Retroviral Vectors
Adeno-Associated Viral Vectors
Others